HPTN 077: No Significant Weight Gain at Week 41 With Long-Acting CAB vs PBO in HIV-Uninfected Persons at Low Risk for Infection

March 4-7, 2019; Seattle, Washington
Post hoc analysis finds no evidence of association between cabotegravir use and weight gain.
Format: Microsoft PowerPoint (.ppt)
File Size: 174 KB
Released: March 11, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Expert discussion of data from AIDS 2020: Virtual on new and established HIV treatment from Drs Lisa Hightow-Weidman and David Wohl, reported by CCO

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Lisa Hightow-Weidman, MD, MPH David A. Wohl, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: September 11, 2020 Expired: September 10, 2021

CCO-Kommentar von Dr. José Arribas zu den bei der Konferenz „AIDS 2020: Virtual“ gewonnenen neuen Daten, bei der optimale ART-Strategien für Erstlinien- und Zweitlinien-Therapien bewertet wurden

José R. Arribas, MD Released: September 8, 2020

Download CCO slides reviewing new HIV data from AIDS 2020 on current ART, long-acting treatment, metabolic effects, COVID-19/HIV, and HIV prevention

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP David A. Wohl, MD
Released: September 8, 2020

Commento CCO del Dott. José Arribas sui nuovi dati da AIDS 2020: Virtual che valutano strategie ART ottimali nel contesto dei trattamenti di prima e seconda linea

José R. Arribas, MD Released: September 8, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue